System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Prof François Roubille is an expert in Cardiology at University Hospital of Montpellier (France). As of October 2026, ScienceLeadR ranks François Roubille in the top 1% of experts worldwide for Heart Failure, Myocardial Ischemia and Cardiomyopathies. François Roubille has authored 595 publications, the most recent in 2026, and is an investigator in 70 clinical trials, 20 of them ongoing. SLR score: 3,041 (community average: 125). How the SLR is computed.

LeadR Profile

Prof François Roubille University Hospital of Montpellier France
3 041 ScienceLeadR Reputation 3041

Unlock

Register Login
Network Map

Cardiology

Subspecialties: Public Health - Biochemistry - Biostatistics

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2006 - 2026
Source: PubMed

Hôpital Arnaud de Villeneuve

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 595

Citations

Citations: 26 614 1st author: 70 Last author: 138 Unique author: 5

Main journals

Arch Cardiovasc Dis 67
Eur Heart J 33
Archives of cardiovascular diseases. Supplements 26
ESC Heart Fail 25
Archives of Cardiovascular Diseases Supplements 22

Best Journals

Eur Heart J 16
N Engl J Med 13
Circulation 4

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Cardiovascular outcomes and acute human metapneumovirus infection in adults: A systematic literature review.
PMID 42674298 — bacterial infections, heart failure, heart, metapneumovirus, communicable diseases, infections		J Infect20260
Milvexian with Antiplatelet Therapy after Acute Coronary Syndrome Event.
PMID 42670965 — safety, hemorrhage, ischemic stroke, stroke, myocardial infarction, acute coronary syndrome, therapeutics		N Engl J Med Top journal20262
Sexual Health in Heart Failure: How Age, Sex, and Dyspnea Interact to Shape Intimacy and Unmet Clinical Needs.
PMID 42895114 — heart failure, heart, sexuality, sex, therapeutics, dyspnea		ESC Heart Fail20260
"Baseline Characteristics and Utilization of Medical Therapies in Acute Hospitalized and Chronic Heart Failure Patients Enrolled in GRASP-HF: Differences Between ICARe-HF and Non-ICARe-HF Centres".
PMID 42867408 — mortality, heart failure, heart, hospital mortality, heart failure, systolic, therapeutics		Eur J Heart Fail20260
Vasoactive intensity predicts mortality beyond SCAI staging in cardiogenic shock.
PMID 42712883 — mortality, shock, cardiogenic, norepinephrine, dobutamine		Eur Heart J Open20260

Clinical Studies 70

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 9 Study Chair: 1 Study Director: 1

By phase:

Phase 3 33
N/A 29
Phase 2 6
Phase 4 2

By status:

Completed 41
Recruiting 14
Active not recruiting 5
Terminated 4
Unknown 4
Not yet recruiting 2

By type:

Interventional 59
Observational 11

By Monocentric/Multicentric:

monocentric 26
multicentric2to4 3
multicentric5to9 5
multicentricup10 36

Main Topics

Cohort/Consortium Investigators 7

Ongoing Clinical Trials

20 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
CLEOPATTRA A research study to look at the effects of treatment with a medicine called coramitug (NNC6019 0001) in people with heart failure due to ATTR amyloidosis
2024-518899-31-00 — heart failure, heart, prealbumin, amyloidosis, research, therapeutics, amyloid, cardiomyopathies, transthyretin amyloid cardiomyopathy, transthyretin amyloidosis		Phase 3Recruiting2025
ACetazolamide in Patients With Heart Failure to Decrease Weight and relIEVE Symptoms
NCT07737964 — acetazolamide, quality of life, mortality, heart failure, heart, tablets, signs and symptoms, diuretics, therapeutics, furosemide		Phase 3Not yet recruiting2026
Lp(a) lowering study of pelacarsen (TQJ230) with background inclisiran in participants with elevated Lp(a) and established ASCVD
2024-516356-18-00 — safety, cardiovascular diseases		Phase 3Recruiting2026
EASi PROTKT A study to test vicadrostat (BI 690517) taken together with empagliflozin in people with type 2 diabetes high blood pressure and cardiovascular disease
2025-521188-11-00 — diabetes mellitus, hypertension, safety, blood, cardiovascular diseases, blood pressure, diabetes mellitus, type 2		Phase 3Recruiting2025
DAPAgliflozine to attenuate cardiac RemOdeling afTEr aCuTe myOcardial infarction
2024-511882-13-01 — myocardial infarction, heart failure, echocardiography, therapeutics		Phase 3Active not recruiting2024

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS